土耳其國防部：在以色列空襲前後，土耳其軍事代表團未曾出現在敘利亞空軍基地。

China’s National Medical Products Administration approved two new drugs: 1) Anfuliqita monoclonal antibody injection (subcutaneous), marketed as Yisaina, from Sansheng Guojian Pharmaceutical (Shanghai) Co., Ltd., for acute gouty arthritis in adults who are contraindicated, intolerant of, or unresponsive to NSAIDs and/or colchicine, or who are unsuitable for repeated steroid use. 2) Fumarate likangkepan capsules, marketed as HengYouDa, from Chengdu Shengdi Pharmaceutical Co., Ltd., approved under the NMPA’s priority review for treatment of adult paroxysmal nocturnal hemoglobinuria (PNH) patients not previously treated with complement inhibitors.

恆指期貨日盤開盤漲1.04%，報25724點，高水229點。